Angiogenic activity of classical hematopoietic cytokines

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 537-543

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Cytokines; Hematopoiesis; Interleukins

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8;

ANGIOGENESIS; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CYTOKINE RESPONSE; ENDOTHELIUM CELL; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVIEW;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CYTOKINES; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84858749792     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.003     Document Type: Review

References (135)

1. Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977, 252:5558-5564.
2. Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313:806-810.
3. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82:7580-7584.
4. Vogt C., Pentz S., Rich I.N. A role for the macrophage in normal erythropoiesis. III. In vitro and in vivo erythropoietin gene expression in macrophage detected by in situ hybridization. Exp Hematol 1989, 17:391-397.
5. Buemi M., Cavallaro E., Floccari F., Sturiale A., Aloisi C., Trimarchi M., et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003, 62:228-236.
6. Yasuda Y., Fujita Y., Musha T., Tanaka H., Shiokawa S., Nakamatsu K., et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001, 106(Suppl. 2):215-222.
7. Masuda S., Kobayashi T., Chikuma M., Nagao M., Sasaki R. The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am J Physiol Endocrinol Metab 2000, 278:E1038-E1044.
8. Conrad K.P., Benyo S.F., Westerhausen-Larsen A., Miles T.M. Expression of erythropoietin by the human placenta. FASEB J 1996, 10:760-768.
9. Fairchil D., Benyo D., Conrad K.P. Expression of the erythropoietin receptor by throphoblast cells in the human placenta. Biol Reprod 1999, 60:861-870.
10. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994, 91:3974-3978.
11. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effector in endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982.
12. Carlini R.G., Reyes A.A., Rothstein A. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995, 47:740-748.
13. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1989, 93:2627-2636.
14. Tordjman R., Delaire S., Plouet J., Ting S., Gaulkard P., Fichelson S., et al. Erythroblasts are a source of angiogenic factors. Blood 2001, 97:1968-1974.
15. Ribatti D., Vacca A., Roccaro A.M., Crivellato E., Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003, 33:891-896.
16. Perelman N., Selvaraj S.K., Batra S., Luck L.R., Erdreich-Epstein A., Coates T.D., et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003, 102:1506-1514.
17. Nakano M., Satoh K., Fukumoto Y., Ito Y., Kagaya Y., Ishii N., et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007, 100:662-669.
18. Welte K., Platzer E., Lu L., Gabrilove J.L., Levi E., Mertelsmann R., et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulation factor. Proc Natl Acad Sci USA 1985, 1520-1530.
19. Souza L.M., Boone T.C., Gabrilove J.L., Lai P.H., Zsebo K.M., Murdock D.C., et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986, 232:61-65.
20. Roberts A.W., Nicola N.A. Granulocyte colony-stimulating factor. Colony stimulating factors: molecular and cellular biology 1997, 203-225. Marcel Dekker, New York. 2nd ed. J.M. Garland, P.J. Quensberry, D.J. Hilton (Eds.).
21. Bussolino F., Wang J.W., De Filippi P., Turrini F., Sanavio F., Edgell C.J., et al. Granulocyte and granulocyte-macrophage colony-stimulating factor induce human endothelial cells to migrate and proliferate. Nature 1989, 377:471-473.
22. Kojima S., Tadenuma H., Inada Y., Saito Y. Enhancement of plasminogen activator activity in cultured endothelial cells by granulocyte colony-stimulating factor. J Cell Physiol 1989, 138:192-196.
23. Bocchietto E., Guglielmetti A., Silvagno F., Taraboletti G., Pescarmona G., Mantovani A., et al. Proliferation and migratory responses of murine microvascular endothelial cells to granulocyte-colony stimulating factor. J Cell Physiol 1993, 155:89-95.
24. Colotta F., Bussolino F., Polentarutti N., Guglielmetti A., Sironi M., Bocchietto E., et al. Differential expression of the common beta and specific alpha chains of the receptors for GM-CSF, IL-3 and IL-5 in endothelial cells. Exp Cell Res 1993, 206:311-317.
25. Soldi R., Primo L., Brizzi M.F., Sanavio F., Aglietta M., Polentarutti N., et al. Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. Blood 1997, 89:863-872.
26. Valdembri D., Serini G., Vacca A., Ribatti D., Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 2002, 16:225-227.
27. Bussolino F., Ziche M., Wang J.M., Alessi D., Morbidelli L., Cremona O., et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest 1991, 87:986-991.
28. Fei R., Penn P.E., Wolf N.S. A method to establish pure fibroblast and endothelial cell colony cultures from murine bone marrow. Exp Hematol 1990, 18:953-957.
29. Rubbia-Brandt L., Sappino A.P., Gabbiani G. Locally applied GM-CSF induces the accumulation of alfa-smooth actin containing myofibroblasts. Virchows Arch B 1991, 60:73-82.
30. Broudy V.C., Kauhasky K., Harlan J.M., Adamson J.M. Interleukin 1 stimulates endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol 1987, 139:464-468.
31. Malone D.G., Pierce J.H., Falko J.P., Metcalfe D.D. Production of granulocyte macrophage colony stimulating factor by primary cultures of unstimulated rat microvascular endothelial cells. Blood 1988, 71:684-702.
32. Rajavashisth T.B., Andalibi A., Territo M.C., Berliner J.A., Navab M. Induction of endothelial cell expression of granulocyte and macrophage-colony stimulating factors by modified low-density lipoproteins. Nature 1989, 344:254-257.
33. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., et al. Bv8 regulates myeloid cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
34. Shojaei F., Zhong C., Wu X., Yu L., Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008, 18:372-378.
35. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediated tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009, 106:6742-6747.
36. Stanley E.R., Bartocci A., Patinkin D., Rosendaal M., Bradley T.R. Regulation of very primitive, multipotent, hemopoietic cell by hemopoietin-1. Cell 1986, 45:667-674.
37. Moore M.A.S., Warren D.J. Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 1987, 84:7134-7138.
38. Koboyashi M., Imamura M., Gotohda Y., Maeda S., Iwasaki H., Sakurada K., et al. Synergistic effect of interleukin-1β and interleukin-3 on the expansion of human hematopoietic progenitor cells in liquid culture. Blood 1991, 78:1947-1953.
39. Brugger W., Heimfeld S., Bemeson R.J., Mertelsmann R., Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995, 333:283-287.
40. Zucali J.R., Du Bois C.M., Oppenheim J.J. Hematopoietic effects of interleukin-1. Colony stimulating factors: molecular and cellular biology 1997, 347-368. Marcel Dekker, New York. 2nd ed. J.M. Garland, P.J. Quensberry, D.J. Hilton (Eds.).
41. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645-2650.
42. Carmi Y., Voronov E., Dotan S., Lahat N., Rahat M.A., Fogel M., et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 2009, 183:4705-4714.
43. Coxon A., Bolon B., Estrada J., Kaufman S., Scully S., Rattan A., et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthr Rheum 2002, 46:2604-2612.
44. Morgan D.A., Ruscetti F.W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976, 193:1007-1008.
45. Cozzolino F., Torcia M., Lucibello M., Morbildelli L., Ziche M., Platt J., et al. Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 1993, 91:2504-2512.
46. Sakkoula E., Pipili-Synetos E., Maragoudakis M.E. Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br J Pharmacol 1997, 122:793-795.
47. Johansson M., Henrikkson R., Bergenheim A.T., Koskinen L.O. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br J Cancer 2000, 83:826-832.
48. Alì G., Boldrini L., Lucchi M., Picchi A., Dell'Omodarme M., Prati Mc, et al. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer 2009, 101:1869-1875.
49. Yang Y.C. Human interelukin-3: an overview. Colony stimulating factors: molecular and cellular biology 1997, 227-254. Marcel Dekker, New York. 2nd ed. J.M. Garland, P.J. Quensberry, D.J. Hilton (Eds.).
50. Dentelli P., Del Sorbo L., Rosso A., Molinar A., Garbarino G., Camussi G., et al. Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. J Immunol 1999, 163:2152-2159.
51. Howard M., Farrar J., Hilfiker M., Johnson B., Takatsu K., Hamaoka T., et al. Identification of a T-cell derived B cell growth factor distinct from interleukin-2. J Exp Med 1982, 155:914-921.
52. Toi M., Harris A.L., Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 1991, 174:1287-1293.
53. Minty A., Asselin S., Bensussan A., Shire D., Vita N., Vyakarnam A., et al. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur Cytokine Net 1997, 8:203-213.
54. Jacobsen S.E., Okkenhaug C., Veiby O.P., Caput D., Ferrara P., Minty A. Interleukin 13: novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells. J Exp Med 1994, 180:75-82.
55. Volpert O.V., Fong T., Koch A.E., Pterson J.D., Waltenbaugh C., Tepper R.I., et al. Inhibition of angiogenesis by interleukin-4. J Exp Med 1998, 188:1039-1046.
56. Nishimura Y., Nitto T., Inoue T., Kode K. STAT6 mediates apoptosis of human coronary arterial endothelial cell by IL-13. Hypert Res 2008, 31:535-541.
57. Nishimura Y., Nitto T., Inoue T., Node K. IL-13 attenuates vascular tube formation via JAK2-STA6 pathway. Circ J 2008, 72:469-475.
58. Haas C.S., Amin M.A., Ruth J.H., Allen B.L., Ahmed S., Pakodzi A., et al. In vivo inhibition of angiogenesis by interleukin-13 therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 2007, 6:2535-2548.
59. Scheller J., Rose-Johns S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006, 195:173-183.
60. Hirano T. Interelukin 6 and its receptor: ten years later. Int Rev Immunol 1998, 16:249-284.
61. Fan Y., Ye J., Shen F., Zhu Y., Yeghiazarians Y., Zhu W., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cerebr Blood Flow Metab 2008, 28:90-98.
62. Motto B., Itin A., Sachs L., Keshet E. Patterns of interleukin 6 gene expression in vivo suggest a role for this cytokine in angiogenesis. Proc Nat Acad Sci USA 1990, 87:3092-3096.
63. Lin Z.Q., Kondo T., Ishida Y., Takayasu T., Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delays wound healing in IL-6-deficient mice. J Leuk Biol 2003, 73:713-721.
64. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118:3367-3377.
65. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
66. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95:2630-2636.
67. Huan S.P., Wu M.S., Shun C.T., Wang H.P., Lin M.T., Kuo M.L., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004, 11:517-527.
68. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-741.
69. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldtsone M.B.A., et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993, 90:1006-1010.
70. Brett F.M., Mizisin A.P., Powell H.C., Campbell I.L. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995, 54:766-775.
71. Miles S.A., Rezai A.R., Saiazar-Gonzales J.F., Vander Meyden M., Stevens R.H., Logan D.M., et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Nat Acad Sci USA 1990, 87:4068-4072.
72. Aoki Y., Jaffe E.S., Chang Y., Jones K., Teruya-Feldstein J., Moore P.S., et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpes virus-encoded interleukin-6. Blood 1999, 93:4034-4043.
73. Giraudo E., Arese M., Toniatti C., Strasly M., Primo L., Mantovani A., et al. IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. J Immunol 1996, 157:2618-2623.
74. Brach M.A., Herrmann F. Interleukin 6: present and future. Int J Clin Lab Res 1992, 29:143-151.
75. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996, 56:45-53.
76. Vacca A., Ribatti D., Roncali L., Ranieri, Serio G., Silvestris F., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503-508.
77. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
78. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997, 150:815-821.
79. Nilsson M.B., Lanley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
80. Mukaida N., Harada A., Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998, 9:9-23.
81. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., Di Pietro L.A., Einer V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
82. Strieter R.M., Kunkel S.L., Elner V.M., Martonyí C.L., Koch A.E., Polverini P.J., et al. Interleukin 8. A corneal factor that induces neovascularization. Am J Pathol 1992, 141:1279-1284.
83. Hu D.E., Hori Y., Fan T.D.F. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993, 17:135-143.
84. Smith D.R., Polverini P.J., Kunkel S.L., Orringer M.B., Whyte R.I., Burdick M.D., et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994, 179:1409-1415.
85. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
86. Shono T., Ono M., Izumi H., Jimi S.I., Matsushima K., Okamoto, et al. Involvement of the transcription factor NF-Kappa B in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996, 16:4231-4239.
87. Salcedo R., Resau J.H., Halverson D., Hudson E.A., Dambach M., Poell D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umblical vein endothelial cells. FASEB J 2000, 14:2055-2064.
88. Chen Z., Malhotra P.S., Thomas G.R., Ondrey F.G., Duffey D.C., Smith C.W., et al. Expression of pro-inflammatory and pro-angiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999, 5:1369-1379.
89. Miller L.J., Kurtzman S.H., Wang Y., Anderson K.H., Lindquist R.R., Kreutzer D.L. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 1998, 18:77-81.
90. Wakefield D., Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye diseases. Cytokine 1992, 4:1-5.
91. Arenberg D., Kunkel S., Polverini P., Glass M., Burdick M., Strieter R. Inhibition of interleukin-8 reduced tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996, 97:2792-2802.
92. Fiorentino D.F., Bond M.W., Mosmann T.R. Th2 clones secrete a factor that inhibits cytokine production by Th1 cells. J Exp Med 1989, 170:2081-2095.
93. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
94. Thaxton J.E., Sharma S. Interleukin 10: a multi-faceted agent of pregnancy. Am J Repr Immunol 2010, 63:482-491.
95. Kobayashi M., Fitz L., Ryan M., Clark S.C., Chan S., Loudon R., et al. Identification and purification of the natural killer stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989, 170:827-846.
96. McKnight A.J., Zimmer G.J., Fogelman I., Wolf S.F., Abbas A.K. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994, 152:2172-2179.
97. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995, 13:251-276.
98. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993, 178:1223-1230.
99. Tahara H., Zeh H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress antitumor immunity to a murine melanoma. Cancer Res 1994, 54:182-189.
100. Nastala C.L., Edington H.D., McKinney T.G., Tahara H., Nalesnik M.A., Brunda M.J., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994, 153:1697-1706.
101. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995, 87:581-586.
102. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibitor of angiogenesis. J Clin Invest 1998, 101:1441-1452.
103. Cao R., Farnebo J., Kurimoto M., Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999, 13:2195-2202.
104. Dias S., Boyd R., Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998, 78:361-365.
105. Cavallo F., Quaglino E., Cifaldi L., Di Carlo E., André A., Bernabei P., et al. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res 2001, 61:3518-3523.
106. Mitola S., Strasly M., Prato M., Ghia P., Bussolino F. IL-12 regulates endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol 2003, 171:3725-3733.
107. Strasly M., Cavallo F., Genua M., Mitola S., Colombo M.P., Forni G., et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001, 166:3890-3899.
108. Sgadari C., Angiolillo A.L., Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996, 87:3877-3882.
109. Haicheur N., Escudier B., Dorval T., Negrier S., De Mulder P.H., Dupuy J.M., et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 1996, 119:28-37.
110. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F.J. Evidence for the involvement of endothelial cell integrin ανβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med 1998, 4:408-414.
111. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999, 93:1612-1621.
112. Lucas M.L., Heller L., Coppola D., Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002, 5:668-675.
113. Palmer K., Hitt M., Emtage P.C., Gyorffy S., Gauldie J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gen Ther 2001, 8:282-290.
114. Halin C., Rondini S., Nilsson F., Berndt A., Kosmehl H., Zardi L., et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002, 20:264-269.
115. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a novel T cell growth factor that interacts with the β chain of the IL-2 receptor. Science 1994, 264:965-968.
116. Kuniyasu H., Ohmori H., Ssaki T., Sasahira T., Yoshida K., Kitaday Y., et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 2003, 9:4802-4810.
117. Badoual C., Bouchaud C., Agueznay Nel H., Mortier E., Hans S., Gey A., et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008, 68:3907-3914.
118. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
119. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2626.
120. Silva-Santos B. Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 2010, 40:1873-1876.
121. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005, 175:6177-6189.
122. Pickens S.R., Volin M.V., Mandelin A.M., Kolls J.K., Pope R.M., Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010, 184:3233-3241.
123. Jaschke E., Zabernigg A., Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999, 38:380-386.
124. Xu X., Sun H., Han C., Wang X., Yu W. Topically applied rhGM-CSF for the wound healing: a systematic review. Burns 2011, 37:729-741.
125. Seiler C., Pohl T., Wustmann K., Hutter D., Nicolet P.A., Windecker S., et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double blind, placebo-controlled study. Circulation 2001, 104:2012-2017.
126. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer. Eur J Cancer 2004, 40:2201-2216.
127. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4:459-460.
128. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
129. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116:4045-4059.
130. Acs G., Acs P., Beckwith S.M., Pitts R.L., Clement E., Wong K., et al. Erythropoietin and erythropoietin receptor expression in human lung cancer. Cancer Res 2001, 61:3561-3565.
131. Olujohungbe A., Handa S., Holmes J. Do erythropoietin accelerate malignant transformation in multiple myeloma?. Postgrad Med J 1987, 73:163-164.
132. Bunworasate U., Arnouk H., Mindermal H., O'Loughlin K.L., Sait S.N.J., Barcos M., et al. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 2001, 98:3492-3494.
133. Mittelman M., Zeidman A., Kanter P., Katz O., Oster H., Rund D., et al. Erythropoietin has an anti-myeloma effect - A hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004, 72:155-165.
134. Baz R., Walker E., Choueiri T.K., Abou Jawde R., Brand C., McGowan B., et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007, 117:162-167.
135. Jadersten M., Malcovati L., Dybedal I., Della Porta M.G., Invernizzi R., Montgomery S.M., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improve survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.